116170-90-2

Basic information

• Product Name: ETHYL 3-AMINO-4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE
• Synonyms: SPECS AN-584/42126138;ETHYL 3-AMINO-4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE;ethyl 3-aMino-4-cyano-5-(Methylthio)-thiophen-2-carboxylate;3-Amino-2-carboethoxy-4-cyano-5-(methylthio)thiophene;Ethyl 3-amino-4-cyano-5-methylsulfanylthiophene-2-carboxylate;3-Amino-4-cyano-5-methylsulfanylthiophene-2-carboxylic acid ethyl ester
• CAS NO: 116170-90-2
• Molecular Formula: C₉H₁₀N₂O₂S₂
• Molecular Weight: 242.32
• Product Categories: Heterocycles series;Thiophenes & Benzothiophenes;Thiophenes & Benzothiophenes
• Mol File: 116170-90-2.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 447.3 °C at 760 mmHg
• Flash Point: 224.3 °C
• Appearance: /
• Density: 1.37
• Vapor Pressure: 3.41E-08mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ETHYL 3-AMINO-4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-AMINO-4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE(116170-90-2)
• EPA Substance Registry System: ETHYL 3-AMINO-4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE(116170-90-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 116170-90-2(Hazardous Substances Data)

Usage

General Description

ETHYL 3-AMINO-4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE is a chemical compound with the molecular formula C10H10N2O2S2. It is a derivative of thiophene and contains an amino group, a cyano group, and a methylthio group. ETHYL 3-AMINO-4-CYANO-5-(METHYLTHIO)THIOPHENE-2-CARBOXYLATE is often used in pharmaceutical and chemical research for its potential biological activities and it may have applications in the development of new drugs. The presence of the thiophene ring in its structure makes this compound a valuable synthetic intermediate for the preparation of various heterocyclic compounds. Its unique chemical properties and potential biological activities make it a subject of interest for further studies and applications.

InChI:InChI=1/C9H10N2O2S2/c1-3-13-8(12)7-6(11)5(4-10)9(14-2)15-7/h3,11H2,1-2H3

Upstream product

• 72436-88-5 ethyl 4-amino-3-methylthiothieno<2,3-c>isothiazole-5-carboxylate 
• 5147-80-8 [Bis(methylthio)methylene]malononitrile 
• 623-51-8 ethyl 2-sulfanylacetate 
• 84911-18-2 ethyl 2-bromoacetoacetate 
• 20602-68-0 potassium (2,2-dicyano-1-methylsulfanylethen-1-yl)thiolate 
• 685-87-0 Diethyl 2-bromomalonate 
• 22009-90-1 diethyl 2-bromo-3-oxo-glutarate 
• 762-21-0 acetylenedicarboxylic acid diethyl ester 

Downstream Products

• 116170-84-4 ethyl 4-cyano-5-methylsulfanylthiophene-2-carboxylate 
• 1370703-69-7 ethyl 4-cyano-5-(methylthio)-3-(3-phenylureido)thiophene-2-carboxylate 
• 1370703-68-6 ethyl 4-cyano-3-(ethoxy(phenylamino)methyleneamino)-5-(methylthio)thiophene 
• 1370703-64-2 6-(methylthio)-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydrothieno[3,2-d]pyrimidine-7-carbonitrile 
• 1370703-63-1 2-ethoxy-6-(methylthio)-4-oxo-3-phenyl-3,4-dihydrothieno[3,2-d]pyrimidine-7-carbonitrile 
• 1370703-59-5 ethyl 4-cyano-5-(methylthio)-3-triphenylphosphiniminothiophene-2-carboxylate 
• 1370703-60-8 ethyl 4-cyano-3-(3-(4-methoxyphenyl)-2,4-diphenyl-1,2,4-oxadiazolidin-5-ylideneamino)-5-(methylthio)thiophene-2-carboxylate 
• 1370703-61-9 C₃₀H₂₆N₄O₃S₂ 
• 1370703-62-0 C₂₉H₂₃ClN₄O₃S₂ 
• 1370703-65-3 6-(methylthio)-2-morpholino-4-oxo-3-phenyl-3,4-dihydrothieno[3,2-d]pyrimidine-7-carbonitrile 
• 1370703-66-4 C₁₉H₁₈N₄OS₂ 
• 1370703-67-5 C₂₀H₂₀N₄OS₂ 

Relevant articles and documents

Determinative role of ring size and substituents in highly selective synthesis of functionalized bicyclic guanidine and tetra substituted thiophene derivatives based on salt adducts afforded by cyclic thioureas and ketene dithioacetal

The condensation of organic salt adducts generated by cyclic thioureas and 2-di(methylsulfanyl)methylenemalononitrile with dialkyl acetylenedicarboxylates selectively leads to either tetrasubstituted thiophenes (2 examples) or hitherto unreported bicyclic guanidine (13 examples) derivatives, with controlling factors being ring size, the substituent on the S-methylisothiourea and the bulk of the substituent on the dialkyl acetylenedicarboxylates. Green solvents, short reaction time; easy purification, high yield and selectivity, are key feature of this protocol in the condensation step. The performances of the reactions in the presence of free-base and a catalyst at room temperature is unprecedented in the synthesis of thiophene frameworks and functionalized bicyclic guanidine scaffolds.

Highly mild approach towards synthesis of tetrasubstituted thiophenes by an organic salt afforded by cyclic thioureas and ketene dithioacetals

An organic salt generated by cyclic thioureas and 2-di(methylsulfanyl)methylene malononitrile in reaction with primary and secondary α-haloketones leads to tetrasubstituted thiophenes without using additional base or catalyst at room temperature. The S-methylisothiourea moiety of this salt as an organocatalyst performs a hybrid function of thiourea and imidazole to activate electrophiles via H-bonding and trigger cyclization via Lewis basicity character, respectively. Interestingly, a green solvent (in two step mode), short reaction time, easy purification, high yield and selectivity accompany this protocol. The structures of the intermediate and afforded adducts are fully characterized by analytical investigations and X-ray crystallography.

Preparation method and use of thiophene compound

The invention belongs to the technical field of pharmaceutical chemistry, and relates to thiophene compounds shown by general formula I, pharmaceutically acceptable salts, solvates or prodrugs and preparation methods thereof. In which substituents L, Ar, R have the meanings given in the specification. The invention also relates to a strong PI3K inhibitory effect of a compound of the general formula I, and also relates to the use of such compounds and pharmaceutically acceptable salts, solvates or prodrugs thereof in the preparation of drugs for the treatment and/or prevention of diseases caused by abnormally high expression of PI3K, in particular in the preparation of drugs for the treatment and/or prevention of cancer.